Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,498 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06895811 | Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC | active not recruiting | Phase 1 | 3 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02298959 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | active not recruiting | Phase 1 | 59 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2026 | clinicaltrials |
| NCT06049576 | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03120624 | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer | active not recruiting | Phase 1 | 34 | Mayo ClinicOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04092270 | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer | active not recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05501054 | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | active not recruiting | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03317158 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder(ADAPT-BLADDER) | active not recruiting | Phase 1 / Phase 2 | 186 | Noah Hahn, M.D.OTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | active not recruiting | Phase 1 / Phase 2 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | active not recruiting | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT01883297 | "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 3 | University Health Network, TorontoOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06147037 | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | active not recruiting | Phase 1 | 13 | AstraZenecaINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT06318273 | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 152 | AbbVieINDUSTRY | 7 | Jun 17, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05789069 | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 83 | HiFiBiO TherapeuticsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT03873805 | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04109729 | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer(Rad2Nivo) | active not recruiting | Phase 1 | 39 | University of UtahOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05200559 | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 25 | Alexander B Olawaiye, MDOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT05806814 | Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer(OU-SCC-EXCITE) | active not recruiting | Phase 1 | 15 | University of OklahomaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03172754 | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 98 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05682443 | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC(PRESERVE-006) | active not recruiting | Phase 1 / Phase 2 | 148 | OncoC4, Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | active not recruiting | Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05691504 | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT04846478 | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | active not recruiting | Phase 1 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04486755 | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | active not recruiting | Phase 1 | 18 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05661955 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT05154994 | Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma(RESOLVE) | active not recruiting | Phase 1 | 9 | University of UtahOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04620603 | Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | active not recruiting | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05271318 | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.(PROTA) | active not recruiting | Phase 1 / Phase 2 | 29 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT03393884 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)(OVATION 2) | active not recruiting | Phase 1 / Phase 2 | 130 | ImunonINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT01590069 | Aerosolized Aldesleukin in Treating Patients With Lung Metastases | active not recruiting | Phase 1 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06303713 | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer | active not recruiting | Phase 1 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05808608 | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 37 | Hao ZengOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT03017131 | Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05245006 | PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer | active not recruiting | Phase 1 | 30 | Robert Flavell, MD, PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04004442 | Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma(COAXIN) | active not recruiting | Phase 1 | 19 | University of OklahomaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766.(FRAME) | active not recruiting | Phase 1 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT01970722 | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | active not recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05122546 | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT01684397 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04943536 | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer(BiolenRT) | active not recruiting | Phase 1 | 20 | Alessa Therapeutics Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 23, 2026source: clinicaltrials